BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 11.4% in December

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 4,400,000 shares, a growth of 11.4% from the December 15th total of 3,950,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the short-interest ratio is currently 3.9 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

Institutional Investors Weigh In On BioAtla

Several large investors have recently modified their holdings of BCAB. XTX Topco Ltd boosted its stake in shares of BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after purchasing an additional 10,384 shares in the last quarter. American Century Companies Inc. boosted its position in BioAtla by 36.1% in the second quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock valued at $59,000 after buying an additional 11,503 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of BioAtla by 2.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 541,199 shares of the company’s stock worth $741,000 after buying an additional 14,737 shares in the last quarter. Vontobel Holding Ltd. bought a new position in shares of BioAtla in the third quarter valued at approximately $28,000. Finally, Chicago Partners Investment Group LLC bought a new stake in BioAtla during the 3rd quarter worth approximately $44,000. 77.23% of the stock is currently owned by institutional investors.

BioAtla Stock Performance

NASDAQ BCAB traded up $0.01 during midday trading on Friday, hitting $0.49. The company had a trading volume of 373,650 shares, compared to its average volume of 1,483,387. The firm has a fifty day simple moving average of $1.17 and a two-hundred day simple moving average of $1.57. BioAtla has a fifty-two week low of $0.45 and a fifty-two week high of $4.02.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same quarter in the previous year, the business earned ($0.70) earnings per share. Equities research analysts forecast that BioAtla will post -1.46 EPS for the current year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.